LinkedIn Image Expert Review on Chronic Myeloid Leukemia

Expert Review on Chronic Myeloid Leukemia

View Activity

Activity Features

Downloadable Slides

Expert Discussion

Opinion Poll

prIME Points™

Activity Overview

Stay informed on the management of chronic myeloid leukemia (CML). This Expert Review features a discussion and downloadable slides focusing on recent updates in CML. Discussion focuses on the options for first-line treatment of CML, options for sequencing the approved tyrosine kinase inhibitors (TKIs), and how comorbidities and adverse events influence treatment decisions.


  • Elias Jabbour, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • François-Xavier Mahon, MD, PhDInstitut Bergonié
    Bordeaux, France


  • Front-line treatment of CML
  • Sequencing TKIs in CML
  • Common adverse events associated with TKIs
  • The role of comorbidities in selecting appropriate treatment of CML

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Describe the efficacy of second‐generation TKIs for CML therapy in first‐line treatment
  • Distinguish the tolerability profiles of available TKIs in order to effectively manage adverse events and select appropriate therapy based on patient preference and underlying comorbidities
  • Identify best practices with respect to monitoring responses and when to switch TKI therapy

Target Audience

This educational activity is designed for Ex‐US oncologists, hematologists, and other healthcare professionals involved and/or interested in the management of patients with CML.

View in EnglishView in French


This activity is provided by prIME Oncology.


This educational activity is supported by Pfizer.

Activity Date

July 28, 2017

July 28, 2018